Market brief

European Antibody & Biosimilar Therapeutics 2026: mAbs, ADCs, Biosimilars

The European antibody + biosimilar therapeutics sector in 2026 spans four overlapping modalities the directory surfaces across 29 operators: clinical and commercial-stage antibody therapeutics (Genmab, Alligator Bioscience, BioArctic, Cantargia, Lipum, Affimed, Alentis), antibody-drug conjugates (ADC Therapeutics, Adcendo, Tubulis, Heidelberg Pharma, Cerbios-Pharma, VERAXA), biosimilars + monoclonal-antibody manufacturing (Sandoz, Mabion, Rezon Bio, Paras Biopharmaceuticals, Icosagen, Glycotope, Bioton), and discovery + platform biotechs (Pure Biologics, Light Chain Bioscience, Memo Therapeutics, Lead Biologics, Calluna Pharma, ANGENOVO). Genmab (Copenhagen) is the Nordic antibody-therapeutics commercial anchor. ADC Therapeutics (Epalinges, Switzerland) and Adcendo (Copenhagen) are the two European ADC-focused operators with the most visible clinical and commercial ADC pipelines. Sandoz (Basel, independent from Novartis since October 2023) is the European biosimilar-manufacturing anchor. Mabion (Łódź) runs antibody biosimilar CDMO services at commercial scope. For sponsors evaluating European antibody or biosimilar partnerships, these 29 operators form the directory-visible landscape.

Summary

Key findings

Commercial + clinical-stage antibody therapeutics anchors: Genmab (Copenhagen, antibody-therapeutics platform), Alligator Bioscience (Lund, immuno-oncology CD40 biology), BioArctic (Stockholm, neurodegenerative antibodies including Leqembi with Eisai partnership), Cantargia (Lund, IL1RAP-targeted oncology antibodies), Lipum (Umeå, BSSL-targeted chronic inflammatory), Affimed (Ladenburg/Heidelberg, innate-immune engagers).
Antibody-drug conjugate (ADC) layer: ADC Therapeutics (Epalinges, Switzerland, commercial ZYNLONTA / loncastuximab tesirine), Adcendo (Copenhagen, pipeline ADCs), Heidelberg Pharma (Heidelberg, ADC + amanitin-based programmes), Tubulis (Munich, clinical-stage ADCs with P5 toxin platform), Cerbios-Pharma (Barbengo, ADC + HPAPI CDMO), VERAXA Biotech (Heidelberg, pipeline antibodies).
Biosimilar + antibody CDMO + mAb manufacturing: Sandoz (Basel, independent Novartis spin-out since October 2023 - the European biosimilar and generics anchor), Mabion (Łódź, antibody biosimilar CDMO), Rezon Bio / Polpharma Biologics (Gdańsk/Warsaw, mammalian cell culture biosimilars), Paras Biopharmaceuticals (Oulu, biologics + biosimilars CDMO), Icosagen Group (Tartu, antibody CDMO + research), Glycotope (Berlin, glycoengineered tumor-specific antibodies), Bioton (Warsaw, insulin biosimilar + biomanufacturing).
Discovery + platform biotechs: Pure Biologics (Wroclaw, antibody + aptamer discovery), Light Chain Bioscience / Novimmune (Plan-les-Ouates, bispecific antibody platform), Memo Therapeutics (Schlieren, antibody discovery), Lead Biologics (Helsingborg), Calluna Pharma (Oslo), ANGENOVO (Rissa, Norway, tools).
First-pass shortlist

Choose the antibody relationship before choosing the company

Antibody therapeutics, ADC development, biosimilar manufacturing, and discovery platforms are distinct routes. Start with the product or service required, then verify programme access, site scope, capacity, and rights directly with the operator.

Therapeutic collaboration or licensing

Antibody or bispecific pipeline developer

Europe-wide

Publicly stated scope
Treat Genmab, Alligator, BioArctic, Cantargia, Lipum, Affimed, Alentis, and similar companies as potential pipeline or platform collaborators based on public programmes.
Confirm first
Target and indication, development stage, rights and territory, partner-access process, evidence package, manufacturing dependencies, and collaboration precedent.
Do not assume
That a public antibody pipeline or approved product indicates an open licensing, co-development, or contract-service opportunity.
ADC development or specialist manufacturing

ADC developer, conjugation specialist, or HPAPI CDMO

Switzerland, Germany, and Denmark

Publicly stated scope
Route ADC therapeutic collaboration to ADC Therapeutics, Adcendo, Heidelberg Pharma, or Tubulis; start with Cerbios-Pharma when the need is publicly described ADC and HPAPI CDMO capability.
Confirm first
Antibody, linker and payload requirements, conjugation chemistry, containment, analytical and comparability package, GMP stage, fill-finish, and the named manufacturing site.
Do not assume
That ADC platform wording confirms external CDMO capacity, a matching payload route, or an available development campaign.
Biosimilar or antibody CDMO

Mammalian-cell-culture, biosimilar, or mAb manufacturing route

Poland, Finland, and Estonia

Publicly stated scope
Start with Mabion, Rezon Bio, Paras Biopharmaceuticals, or Icosagen when the requirement is a publicly described external antibody or biosimilar manufacturing and development route.
Confirm first
Molecule and cell line, process-development starting point, scale, analytical similarity strategy, GMP phase, technology transfer, release testing, and product-specific regulatory plan.
Do not assume
That a biosimilar or mAb description proves commercial capacity, regulatory comparability, or availability for the particular molecule.
Commercial biosimilar supply

A marketed biosimilar or generics portfolio owner

Basel, Switzerland

Publicly stated scope
Treat Sandoz as a commercial biosimilar and generics company when the need concerns its public product portfolio, market access, or a commercial partnership discussion.
Confirm first
Specific product, market and distribution rights, supply status, pharmacovigilance and quality responsibilities, and the appropriate commercial contact.
Do not assume
That a commercial biosimilar manufacturer is a general-purpose CDMO for third-party molecules.
Antibody discovery or platform science

Discovery, screening, or engineering platform

Poland, Switzerland, Sweden, and Norway

Publicly stated scope
Start with Pure Biologics, Memo Therapeutics, Light Chain Bioscience, Lead Biologics, or Calluna only when the desired relationship is early discovery, screening, or platform collaboration.
Confirm first
Discovery modality, target class, screening and engineering workflow, IP ownership, data package, transfer point, developability work, and the collaboration model.
Do not assume
That a discovery platform provides clinical manufacturing, therapeutic rights, or a validated lead for a specific target without a separate programme.
Numbers

Quick numbers

Operators in the directory29Antibody therapeutics + ADC + biosimilar + discovery
ADC layer6 operatorsIncluding 1 commercial product (ADC Therapeutics ZYNLONTA)
Biosimilar manufacturingSandoz + 6 CDMOsSwiss anchor + Polish/Finnish/Estonian CDMO layer
Nordic antibody anchorGenmabCopenhagen commercial-stage antibody platform
Analysis

Antibody therapeutics: Nordic + German + Swedish innovator belt

The European antibody-therapeutics layer concentrates in two overlapping clusters. Genmab (Copenhagen) runs the Nordic antibody-therapeutics commercial platform with partnered commercial products (DARZALEX with J&J confirmed publicly, plus the TEPKINLY / EPKINLY franchise with AbbVie confirmed in Genmab disclosures) and a deep oncology pipeline. In Sweden, the antibody-innovator belt covers Lund (Alligator Bioscience for CD40 biology and immuno-oncology antibodies; Cantargia for IL1RAP-targeted oncology; Lipum in Umeå for BSSL-targeted chronic inflammatory therapeutics), Stockholm (BioArctic for neurodegenerative antibodies with the Leqembi / lecanemab partnership with Eisai disclosed publicly), and Helsingborg (Lead Biologics). Germany adds Affimed (Heidelberg/Ladenburg) for innate-immune engagers (NK-cell-based bispecific antibodies), VERAXA Biotech (Heidelberg) for pipeline antibodies, Glycotope (Berlin) for glycoengineered antibodies, and Tubulis (Munich) for clinical-stage ADCs. Switzerland adds Alentis Therapeutics (Basel) for fibrosis and oncology antibodies, plus Memo Therapeutics (Schlieren) and Light Chain Bioscience (Plan-les-Ouates) for bispecific and light-chain-based platforms.

Analysis

Antibody-drug conjugates (ADCs): a specialised European cluster

ADCs are the most commercially active antibody sub-modality in 2026. ADC Therapeutics (Epalinges, Switzerland) runs the European ADC commercial story with ZYNLONTA (loncastuximab tesirine) as its approved product for relapsed / refractory large B-cell lymphoma and a broader pipeline behind it. Adcendo (Copenhagen, Denmark) runs clinical-stage ADCs with the Adcendo pipeline. Heidelberg Pharma (Heidelberg, Germany) develops ADC platforms using amanitin-based payloads. Tubulis (Munich) operates clinical-stage ADCs using its P5 toxin conjugation platform. Cerbios-Pharma (Barbengo, Switzerland) provides ADC + HPAPI CDMO services as part of the Swiss specialty-manufacturing layer. VERAXA Biotech (Heidelberg) adds pipeline-stage antibody + ADC programmes. Together, six directory operators cover the European ADC stack from discovery + platform through clinical + commercial scope.

Analysis

Biosimilars: Sandoz + Mabion + Polpharma + Paras

The European biosimilar manufacturing layer has narrowed since the Sandoz spin-out. Sandoz (Basel, independent listed company on SIX since October 2023 when Novartis completed the spin-out) is the only directory-surfaced European operator running biosimilars at in-house commercial manufacturing scale - the others operate as CDMOs, not product owners. Mabion (Łódź, Poland) runs antibody biosimilar CDMO services at commercial scope, supporting sponsors developing biosimilar versions of originator mAbs. Rezon Bio (Gdańsk / Warsaw, rebranded Polpharma Biologics CDMO arm) runs biosimilar manufacturing and mammalian cell culture CDMO services. Paras Biopharmaceuticals (Oulu, Finland) adds biologics + biosimilars + recombinant-protein process development and CDMO services. Icosagen Group (Tartu, Estonia) runs antibody CDMO + research services. Glycotope (Berlin) licenses glyco-legacy IP alongside development-stage programmes. Bioton (Warsaw) runs insulin biomanufacturing at commercial scope (an insulin-generic adjacent to the biosimilar layer). For sponsors running biosimilar programmes, these seven operators cover the directory’s biosimilar + antibody-CDMO layer.

Analysis

Discovery and platform biotechs

European antibody discovery operates through a discovery + platform layer the directory surfaces. Pure Biologics (Wroclaw, Poland) runs antibody + aptamer discovery services. Light Chain Bioscience / Novimmune (Plan-les-Ouates, Switzerland) operates a bispecific-antibody platform using its light-chain technology. Memo Therapeutics (Schlieren, Switzerland) develops antibody discovery and clinical-stage programmes. Lead Biologics (Helsingborg, Sweden) and Calluna Pharma (Oslo, Norway) add regional discovery layers. ANGENOVO (Rissa, Norway) provides antibody development tools. For sponsors looking for European discovery or bispecific-platform partners, this cluster covers the core directory options.

Analysis

How ADC and antibody therapeutics connect to the CDMO supply chain

Antibody + ADC therapeutics have a specialised supply chain the directory surfaces. For the antibody drug substance, the European biologics CDMOs the directory covers - Lonza (Visp), Rentschler Biopharma (Laupheim), FUJIFILM Diosynth Denmark (Hillerod), AGC Biologics (Heidelberg + Soborg), Vetter Pharma (Ravensburg fill-finish), Celonic (Basel), FyoniBio (Heidelberg), AGC Biologics Heidelberg - form the core shortlist (see the European CDMO Capacity 2026 brief). For the ADC conjugation step, Cerbios-Pharma (Barbengo) and CARBOGEN AMCIS (Bubendorf) cover ADC + HPAPI capacity. For biosimilar manufacturing, Mabion and Rezon Bio are the Polish options, Paras Biopharmaceuticals is the Finnish option, Icosagen is the Baltic option. Sandoz manufactures biosimilars in-house at scale. Synthetic-API inputs (peptides, oligonucleotides) route through Bachem (Bubendorf) and BioSpring (Frankfurt). The European CDMO Capacity 2026 and Swiss Biotech Landscape 2026 briefs cover the manufacturing layer in more depth.

Analysis

How to pick an antibody, ADC, or biosimilar partner in 2026

Match the decision to the modality. Commercial antibody partnership or licensing: Genmab (Copenhagen) is the Nordic commercial-stage antibody operator with disclosed partnerships (Janssen, AbbVie). Clinical antibody therapeutics: Alligator Bioscience, BioArctic, Cantargia, Affimed, Alentis Therapeutics, Tubulis. ADC clinical + commercial: ADC Therapeutics (ZYNLONTA commercial), Adcendo, Heidelberg Pharma, Tubulis. ADC + HPAPI CDMO: Cerbios-Pharma or CARBOGEN AMCIS (see the Swiss Biotech Landscape 2026 brief). Antibody biosimilar CDMO: Mabion (Polish), Rezon Bio (Polish), Paras Biopharmaceuticals (Finnish), Icosagen (Estonian). In-house biosimilar manufacturing at commercial scale: Sandoz (Swiss, the directory’s only in-house biosimilar product owner at that scope). Insulin biomanufacturing: Bioton (Polish). Discovery and platform partners: Pure Biologics, Light Chain Bioscience, Memo Therapeutics, Lead Biologics. The How to Pick a European Biotech Partner 2026 brief covers cross-modality partner selection.

What to watch

What to watch next

Genmab TEPKINLY / EPKINLY commercial progression and pipeline antibody disclosures
ADC Therapeutics ZYNLONTA commercial progression and pipeline ADC readouts
BioArctic + Eisai Leqembi lecanemab commercial rollout in Europe (post-EMA approval)
Sandoz biosimilar pipeline decisions as an independent company (post-October-2023 spin-out)
Tubulis P5-toxin ADC and Heidelberg Pharma amanitin-ADC clinical progression
Mabion biosimilar commercial-stage progression + new antibody CDMO contracts
FAQ

Frequently asked questions

Who are the main European antibody therapeutics companies in 2026?

Genmab (Copenhagen) is the Nordic commercial anchor with partnered products (DARZALEX with J&J, TEPKINLY / EPKINLY with AbbVie). In Sweden, Alligator Bioscience (Lund, CD40 immuno-oncology), BioArctic (Stockholm, Leqembi partnered with Eisai for Alzheimer’s), Cantargia (Lund, IL1RAP oncology), and Lipum (Umeå). Germany adds Affimed (innate-immune engagers), Heidelberg Pharma (ADCs), and Tubulis (ADCs). Switzerland adds Alentis Therapeutics, plus discovery-platform biotechs Memo Therapeutics and Light Chain Bioscience (Novimmune).

Who runs European ADC (antibody-drug conjugate) programmes?

ADC Therapeutics (Epalinges, Switzerland) runs the European commercial ADC story with ZYNLONTA (loncastuximab tesirine). Adcendo (Copenhagen) runs clinical-stage ADCs. Heidelberg Pharma (Heidelberg) develops ADCs with amanitin payloads. Tubulis (Munich) develops ADCs using its P5 toxin conjugation platform. VERAXA Biotech (Heidelberg) adds pipeline antibody + ADC programmes. On the CDMO side, Cerbios-Pharma (Barbengo) and CARBOGEN AMCIS (Bubendorf) provide ADC + HPAPI manufacturing capacity.

Is Sandoz still part of Novartis?

No. Sandoz was spun out of Novartis as an independent SIX-listed company in October 2023. As of 2026 Sandoz operates as the European biosimilar and generics anchor headquartered in Basel, independent from Novartis. It is the only directory-surfaced European operator running biosimilars at in-house commercial manufacturing scale - the others are CDMOs, not product owners.

Where can I find antibody biosimilar CDMO capacity in Europe?

Four directory operators cover antibody biosimilar CDMO work: Mabion (Łódź, Poland) runs antibody biosimilar CDMO services at commercial scope; Rezon Bio / Polpharma Biologics (Gdańsk / Warsaw, Poland) runs biosimilar manufacturing and mammalian cell culture; Paras Biopharmaceuticals Finland (Oulu) runs biologics + biosimilars + recombinant-protein process CDMO; Icosagen Group (Tartu, Estonia) runs antibody CDMO + research services. Sandoz manufactures its biosimilars in-house at scale.

What European companies work on bispecific antibodies?

Affimed (Heidelberg / Ladenburg, Germany) runs innate-immune engagers using bispecific-antibody formats (NK-cell based, ROCK technology). Light Chain Bioscience / Novimmune (Plan-les-Ouates, Switzerland) operates a bispecific antibody platform using its proprietary light-chain technology. Memo Therapeutics (Schlieren) works on antibody discovery including multispecific formats. Pure Biologics (Wroclaw) runs bispecific + aptamer discovery.

Methodology note

Sources and interpretation

Sources: verified Memel Biotech directory entries for every antibody + ADC + biosimilar operator, official company disclosures, partnering announcements (Genmab + J&J + AbbVie, BioArctic + Eisai), and editorial comparison against the European CDMO Capacity 2026 and Swiss Biotech Landscape 2026 briefs. The directory entry for each operator links to the authoritative company sources.

Disclaimer

Use limits

This brief is an editorial map of visible European antibody + ADC + biosimilar therapeutics activity in 2026. Product names, partnerships, and clinical-stage claims reflect publicly disclosed information as of directory review - verify directly with each operator before engagement.

Primary sources

Source list

Genmab corporate overviewADC Therapeutics ZYNLONTABioArctic corporate overviewSandoz (independent Novartis spin-out)Mabion antibody biosimilar CDMO
Related pages

Related directory records

Verification methodologyLithuania biotech page (LT)
Briefs

Continue through related topics.

A useful brief should help people move into related records, cities, categories, and methodology pages without falling back into generic template language.

All briefsDirectory home